Theriva Biologics, Inc.

0.27 USD
+0.00 (+1.87%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Theriva Biologics, Inc. stock is up 11.21% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 21.88% of the previous 31 July’s closed higher than June.

About Theriva Biologics, Inc.

Synthetic Biologics, Inc. develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade intravenous beta-lactam antibiotics in gastrointestinal (GI) tract. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.